Nrf2 activation protects against lithium-induced nephrogenic diabetes insipidus

Lithium (Li) is the mainstay pharmacotherapeutic mood stabilizer in bipolar disorder. Its efficacious use is complicated by acute and chronic renal side effects, including nephrogenic diabetes insipidus (NDI) and progression to chronic kidney disease (CKD). The nuclear factor erythroid-derived 2–rel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Jobbagy, Soma, Vitturi, Dario A., Salvatore, Sonia R., Pires, Maria F., Rowart, Pascal, Emlet, David R., Ross, Mark, Hahn, Scott, St. Croix, Claudette, Wendell, Stacy G., Subramanya, Arohan R., Straub, Adam C., Tan, Roderick J., Schopfer, Francisco J.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7030822/
https://ncbi.nlm.nih.gov/pubmed/31941842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.128578
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars